Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,179,473
  • Shares Outstanding, K 104,110
  • Annual Sales, $ 482,380 K
  • Annual Income, $ 106,140 K
  • EBIT $ 128 M
  • EBITDA $ 121 M
  • 60-Month Beta 0.46
  • Price/Sales 10.22
  • Price/Cash Flow 49.25
  • Price/Book 8.27

Options Overview Details

View History
  • Implied Volatility 94.08% ( -7.86%)
  • Historical Volatility 39.75%
  • IV Percentile 84%
  • IV Rank 56.10%
  • IV High 156.92% on 05/17/24
  • IV Low 13.78% on 08/16/24
  • Put/Call Vol Ratio 0.73
  • Today's Volume 1,458
  • Volume Avg (30-Day) 923
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 22,809
  • Open Int (30-Day) 23,909

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.34
  • Low Estimate 0.20
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.92 +17.15%
on 09/23/24
50.07 -1.92%
on 10/18/24
+6.86 (+16.24%)
since 09/20/24
3-Month
32.33 +51.90%
on 08/05/24
50.07 -1.92%
on 10/18/24
+15.23 (+44.95%)
since 07/19/24
52-Week
20.84 +135.65%
on 04/22/24
50.07 -1.92%
on 10/18/24
+21.19 (+75.90%)
since 10/20/23

Most Recent Stories

More News
Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $12 Put had some of the highest...

CORT : 49.11 (-1.29%)
Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

For Immediate ReleaseChicago, IL – October 10, 2024 – Stocks in this week’s article are Corcept Therapeutics Inc. CORT, Abercrombie & Fitch Co. ANF and HCI Group, Inc. HCI.3 Strong Buy Momentum Stocks...

CORT : 49.11 (-1.29%)
ANF : 159.89 (+2.00%)
HCI : 115.81 (-3.38%)
3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Entering the fourth quarter of 2024, Wall Street maintained strong momentum, positively closing the first nine months. The S&P 500, the Dow and the Nasdaq gained 20.8%, 12.3% and 21.2%, respectively, in...

CORT : 49.11 (-1.29%)
ANF : 159.89 (+2.00%)
HCI : 115.81 (-3.38%)
Here's Why Investors Should Consider Buying Corcept Stock Now

Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past...

CORT : 49.11 (-1.29%)
KRYS : 178.98 (-0.12%)
ANIP : 59.28 (-1.71%)
BVS : 12.74 (-1.62%)
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – With the recent wrapping up of...

ONCY : 1.2600 (-6.67%)
CORT : 49.11 (-1.29%)
ILMN : 145.21 (-0.59%)
CSTL : 31.87 (-2.36%)
NUVL : 101.17 (-2.43%)
ONC.TO : 1.76 (-4.86%)
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $12.00 Put had some of the highest...

CORT : 49.11 (-1.29%)
Corcept: Q2 Earnings Snapshot

Corcept: Q2 Earnings Snapshot

CORT : 49.11 (-1.29%)
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fall

CORT : 49.11 (-1.29%)
ET : 16.40 (-0.06%)
USM : 61.21 (-2.76%)
AY : 21.97 (-0.14%)
DKNG : 37.16 (-3.38%)
AGIO : 45.66 (+0.35%)
INSM : 72.28 (-3.03%)
Corcept: Q1 Earnings Snapshot

Corcept: Q1 Earnings Snapshot

CORT : 49.11 (-1.29%)
Corcept: Q4 Earnings Snapshot

Corcept: Q4 Earnings Snapshot

CORT : 49.11 (-1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 51.26
2nd Resistance Point 50.63
1st Resistance Point 49.87
Last Price 49.11
1st Support Level 48.48
2nd Support Level 47.85
3rd Support Level 47.09

See More

52-Week High 50.07
Last Price 49.11
Fibonacci 61.8% 38.90
Fibonacci 50% 35.46
Fibonacci 38.2% 32.01
52-Week Low 20.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar